<?xml version="1.0" encoding="UTF-8"?>
<p>Cancer is a multigenetic disease with the hallmark that multiple signalling pathways aberration, which often require multiple therapeutic interventions
 <xref rid="CIT0001" ref-type="bibr">
  <sup>1</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0002" ref-type="bibr">
  <sup>2</sup>
 </xref>. Kinases mediate various cellular activities due to their critical roles in cellular signalling, such as proliferation, apoptosis, transcription, differentiation and so on
 <xref rid="CIT0003" ref-type="bibr">
  <sup>3</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0004" ref-type="bibr">
  <sup>4</sup>
 </xref>, which have been demonstrated as promising drug targets for the treatment of many diseases such as cancers
 <xref rid="CIT0005" ref-type="bibr">
  <sup>5â€“7</sup>
 </xref>. Kinase inhibitors are widely employed in clinical oncology
 <xref rid="CIT0008" ref-type="bibr">
  <sup>8</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0009" ref-type="bibr">
  <sup>9</sup>
 </xref>. Simultaneous inhibition of different mechanisms using multi-kinase inhibitors could yield superior efficacy, such as synergy effects, avoiding drug resistance and so on
 <xref rid="CIT0010" ref-type="bibr">
  <sup>10</sup>
 </xref>.
</p>
